| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03026803 Details | 2017-04-13 Interventional | 2 | 4 | Capecitabine Oxaliplatin Carcinoma, Hepa… Liver Neoplasms Hepatocellular … Liver Cancer | Due to Sorafenib became first line treatment for HCC, the designed treatment became less
competitive. The company Sanofi decided not to continue to support Due to Sorafenib becoming a first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue support. Study was terminated after accrual of 4 of the 32 planned patients. | |||
| NCT02387242 Details | 2017-04-13 Interventional | 1 | - | Rifampin Tuberculosis | New relevant data published - | |||
| NCT01037335 Details | 2017-04-13 Interventional | 4 | 0 | Morphine Autogenous Bone… | No participants enrolled - | |||
| NCT03110952 Details | 2017-04-12 Interventional | 1 | 0 | Vaccines alpha-Tocophero… Dengue | lack of materials, not moving forward - | |||
| NCT02145676 2013-002346-37 Details | 2017-04-12 Interventional | 3 | 53 | Botulinum Toxin… Botulinum Toxin… abobotulinumtox… Muscle Spastici… Stroke | - - | |||
| NCT01754376 Details | 2017-04-12 Interventional | 2 | 6 | Aldesleukin Interleukin-2 Vemurafenib Melanoma | changes in available treatments for melanoma The protocol terminated early due to a dramatic change in the treatment landscape for treating BRAF mutant melanoma (e.g. one BRAF/MEK inhibitor combination and two anti-PD1 antibodies were approved by the FDA while this study was open). | |||
| NCT00833053 2008-000454-12 Details | 2017-04-12 Interventional | 3 | 39 | Infliximab Methotrexate Psoriasis | In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was discontinued
due to low numbers of participants with suboptimal response. - | |||
| NCT00537316 Details | 2017-04-12 Interventional | 3 | [1 Refs] | 242 | Azathioprine Infliximab Colitis Colitis, Ulcera… Ulcer Ulcerative Coli… | Infusion reactions during re-induction cycles after a period of no treatment in another study
[P04563, NCT0358670] - | ||
| NCT01153919 Details | 2017-04-11 Interventional | 2 | 27 | Interferon alph… Interferon-alph… Interferons Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C Thrombocytopeni… Hepatitis C Inf… | Approval of several new agents for the treatment of HCV infection would mitigate the future
need for interferon HCV treatment - | |||
| NCT01151449 Details | 2017-04-11 Interventional | 2 | 6 | 2,2-dimethyl-N-… Breast Neoplasm… Breast Neoplasm… Recurrence Triple Negative… Estrogen Recept… HER2-negative B… Male Breast Can… Progesterone Re… Recurrent Breas… Stage IIIA Brea… Stage IIIB Brea… Stage IIIC Brea… Stage IV Breast… Triple-negative… | Administratively Complete - | |||
| NCT00358670 2005-005367-28 Details | 2017-04-11 Interventional | 3 | [1 Refs] | 441 | Infliximab Psoriasis | Infusion reactions during re-induction cycles after a period of no treatment. Please see
"Purpose" section. - | ||
| NCT02044302 Details | 2017-04-10 Interventional | 2 | 2 | Analgesics Botulinum Toxin… Bupivacaine Morphine Narcotics Pain, Postopera… Post-operative … | - - | |||
| NCT01140399 Details | 2017-04-10 Interventional | 4 | 10 | Dopamine Furosemide Cardio-Renal Sy… Heart Failure Acute Decompens… | insufficient enrollment - | |||
| NCT00126451 Details | 2017-04-10 Interventional | 2 | 16 | Vorinostat Carcinoma, Non-… Breast Cancer Colorectal Canc… Non-small-cell … | - - | |||
| NCT02413827 Details | 2017-04-07 Interventional | 1/2 | 9 | Antibodies, Mon… Ipilimumab Poly ICLC Melanoma Unresectable St… | Feasibility concerns due to changes in standard of care - | |||
| NCT02200380 Details | 2017-04-07 Interventional | 2 | 36 | Plerixafor Hodgkin Disease Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Lymphoma, Non-H… Myelodysplastic… Precursor Cell … Preleukemia Acute Lymphobla… Acute Myelogeno… Chronic Lymphoc… Chronic Myeloge… For Donors For Recipients Hodgkins Diseas… Myelodysplastic… Non-Hodgkins Ly… Related Donors … | - - | |||
| NCT02071641 Details | 2017-04-07 Interventional | 2 | 5 | Sunitinib Carcinoma Carcinoma, Rena… Metastatic Rena… | - - | |||
| NCT01195727 Details | 2017-04-07 Interventional | 1 | 13 | Apixaban Thromboembolism Venous Thromboe… | - - | |||
| NCT02571283 Details | 2017-04-06 Interventional | 4 | 0 | Bupivacaine Epinephrine Pain Management Total Knee Arth… | PI decided to focus on more current topics of interest. - | |||
| NCT02227108 Details | 2017-04-06 Interventional | 2 | 37 | Immunotoxin HA2… Leukemia Leukemia, Lymph… Lymphoma Precursor Cell … B-Cell Pediatri… | The study was terminated prior to a planned interim analysis based on lack of required efficacy
in the first 32 participants enrolled. The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled. |